Approval Year
| Substance Class |
Concept
|
| Record UNII |
65RC2F9XAB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
883922
Created by
admin on Sat Dec 16 19:00:40 UTC 2023 , Edited by admin on Sat Dec 16 19:00:40 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65RC2F9XAB
Created by
admin on Sat Dec 16 19:00:40 UTC 2023 , Edited by admin on Sat Dec 16 19:00:40 UTC 2023
|
PRIMARY |
This is a non-substance concept
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> ACTIVATOR |
CPO107 is to bind to CD20 on the target cell surface to induce the antibody-dependent cellmediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)
IN-VIVO
|
||
|
|
TARGET->LIGAND |
CPO107 binds to CD47 on the target
cell surface blocking the CD47/SIRPα interaction between the target cell and macrophage, thus, promotes the antibody-dependent cellular phagocytosis (ADCP).
IN-VIVO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
The mechanisms of action of JMT601 cytotoxicity in CD20/CD47 dual positive cancer cells are via ADCC, CDC and ADCP
|
This is a non-substance concept